uniQure (NASDAQ:QURE) Share Price Passes Above 50 Day Moving Average - What's Next?

Key Points

• Technical breakout: uniQure's shares crossed above the 50‑day moving average (50‑day MA $17.04), trading as high as $18.65 and last at $17.90 on volume of 1,295,324 shares, though the stock remains below its 200‑day MA of $26.43.
• Analyst outlook: the consensus is a "Moderate Buy" with an average price target of $42.83 (10 Buys, 6 Holds, 1 Sell), signaling implied upside despite mixed views.
• Fundamentals and insider activity: uniQure topped Q earnings and revenue estimates (EPS -$0.56 vs. -$0.93; revenue $5.57M vs. $4.84M), while insiders have recently sold shares (total 49,396 in 90 days) and institutions own about 78.8% of the stock.

uniQure N.V. (NASDAQ:QURE - Get Free Report)'s share price crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $17.04 and traded as high as $18.65. uniQure shares last traded at $17.90, with a volume of 1,295,324 shares.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on QURE shares. Leerink Partners reiterated an "outperform" rating and set a $35.00 price objective on shares of uniQure in a research note on Monday, March 2nd. Cantor Fitzgerald reiterated a "neutral" rating and set a $9.00 price objective (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Wolfe Research started coverage on uniQure in a research note on Monday, February 23rd. They set a "peer perform" rating on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of uniQure in a research note on Wednesday, January 21st. Finally, Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, March 28th. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, uniQure presently has a consensus rating of "Moderate Buy" and an average price target of $42.83.

uniQure Price Performance

The company has a debt-to-equity ratio of 0.25, a quick ratio of 10.43 and a current ratio of 10.43. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -5.19 and a beta of 0.75. The business has a fifty day moving average of $17.04 and a two-hundred day moving average of $26.43.

uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping analysts' consensus estimates of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. As a group, research analysts predict that uniQure N.V. will post -3.6 EPS for the current fiscal year.

Insider Buying and Selling at uniQure

In other uniQure news, CFO Christian Klemt sold 12,000 shares of the company's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $108,720.00. Following the transaction, the chief financial officer directly owned 226,581 shares of the company's stock, valued at $2,052,823.86. This represents a 5.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Jeannette Potts sold 3,412 shares of the company's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the transaction, the insider directly owned 138,483 shares in the company, valued at approximately $1,254,655.98. This represents a 2.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 49,396 shares of company stock valued at $722,734 in the last ninety days. 4.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QURE. Private Trust Co. NA bought a new stake in shares of uniQure during the 3rd quarter valued at $28,000. Jones Financial Companies Lllp lifted its position in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 509 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of uniQure by 5.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company's stock valued at $243,000 after acquiring an additional 533 shares during the period. Arizona State Retirement System lifted its position in shares of uniQure by 6.0% during the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company's stock valued at $267,000 after acquiring an additional 627 shares during the period. Finally, Ensign Peak Advisors Inc lifted its position in shares of uniQure by 21.7% during the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company's stock valued at $87,000 after acquiring an additional 650 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.